F]AV-1451binding characteristics differ across the PPA variants and were excellent at distinguishing between the variants. [ 18 F]AV-1451binding characteristics were as good or better than other brain imaging modalities utilized in clinical practice, suggesting that [ 18 F]AV-1451 may have clinical diagnostic utility in PPA.
ANN NEUROL 2018;83:599-611 P rimary progressive aphasia (PPA) is an umbrella term that encompasses a group of neurodegenerative syndromes characterized by varying combinations of progressive language impairments. 1, 2 Three clinical variants of PPA have been well described and are well recognized 3 :
the agrammatic/nonfluent variant (agPPA) characterized by grammatical errors in speech and writing and sometimes associated with apraxia of speech 4 ; the semantic variant (svPPA) characterized by grammatically and prosodically normal (ie, fluent) speech with poor naming from loss of knowledge about the meaning of words; and the logopenic variant (lvPPA) characterized by hesitant speech from word retrieval problems, poor sentence repetition from impairment of working memory, and phonological errors.
Pathological studies have demonstrated that PPA is associated with a number of different abnormal cellular proteins that do not have perfect associations with the three PPA variants. [4] [5] [6] [7] [8] One such protein is the microtubule-associated protein, tau, which is the most common abnormal protein found in the brains of patients with PPA. 6 Tau is an important protein that has been linked to the neurodegenerative process in many diseases. Differential splicing of three exons in the tau gene yields three different isoforms of abnormally deposited tau in neurodegenerative diseases 9 : tau with predominantly four microtubule binding domains (4R tau); tau with three microtubule binding domains (3R tau); and tau with almost equal amounts of both (3R14R tau). Understanding tau isoform deposition is important in PPA because pathological studies have shown an association between lvPPA and 3R14R tau, and an association between agPPA and 4R tau. [4] [5] [6] [7] [8] The svPPA variant is rarely associated with tau isoforms 6, 10 and is more commonly associated with another protein, the TAR DNA binding protein of 43 kDa (TDP-43). 6, 8, 10 With that said, pathological studies are limited by sampling small pieces of brain tissue and therefore cannot reveal patterns of tau deposition across the whole brain in PPA variants. Recently, tau PET (positron emission tomography) imaging has become available, which allows for assessment of tau deposition across the entire brain during life. One imaging ligand, [ 18 F]AV-1451 (formerly 18F-T807), has been shown to specifically bind to tau in humans. 11 More recently, with autoradiographic studies, it has been shown that 18 F]AV-1451 binds robustly to 3R14R tau, whereas the binding to 4R tau is inconclusive. [12] [13] [14] [15] [16] ]AV-1451 tau-PET scan, and a Pittsburgh compound B (PiB) PET scan to assess for beta-amyloid deposition. One additional patient signed consent but did not complete neuroimaging testing because of claustrophobia and was therefore not included in this study. In addition, 1 PPA patient could not be subclassified into one of the three wellrecognized PPA variants. 3 As a result, 40 patients were included in this study.
Controls
Using the Mayo Clinic Study of Aging cohort, 17 analysis) 27 and The Rey-Osterrieth complex figure), 25 
PPA Classification
All 40 patients included in this study were evaluated by a behavioral neurologist (K.A.J. or J.G.R.) and had to first meet root diagnostic criteria for PPA 1,2 to be included in the study.
Each patient was then subclassified into one of the three PPA variants based on guidelines from the International Consensus Criteria. Table 1 .
Image Acquisition
All PET scans were acquired using a PET/CT (computed tomography) scanner (GE Healthcare, Milwaukee, WI) operating in three-dimensional mode. Standard corrections were applied. Emission data was reconstructed into a 256 3 256 matrix with a 30-cm field of view (pixel size 5 1.0mm; slice thickness51.96mm). A global PiB standard uptake value ratio (SUVR) was also generated for each patient in the study, as previously described. 32 All subjects had a 3T MPRAGE sequence performed on the same day as the tau-PET, as previously described. 
Voxel-Level Analysis of [ 18 F]AV-1451 in the PPA Variants
All image processing steps were performed using SPM12 (www. fil.ion.ucl.ac.uk/SPM). Voxel-level analyses of [ images were each registered to the subject's magnetizationprepared rapid gradient echo (MPRAGE) using six degrees-offreedom registration. Normalization parameters were computed between each MPRAGE and the Mayo Clinic Adult Lifespan Template (MCALT) (https://www.nitrc.org/projects/mcalt/) using ANTs. 33 With these parameters, the MCALT atlases were propagated to native MPRAGE space, and all voxels in the [ 18 F]AV-1451 image were divided by the median uptake in the cerebellar crus gray matter to create SUVR images. These SUVR images were normalized to the MCALT and smoothed at 6mm full width at half maximum. Voxel-level comparisons were performed comparing each PPA variant to controls using two-sided T-tests in SPM12, with results assessed at p < 0.05 after cluster-level correction for multiple comparisons using the family-wise error correction. Age and sex were included in all first aim analyses as covariates.
Generation of Regional Data for Principal Component Analyses
To generate region-level data to be used in our second and third aims, the MCALT atlas was transformed into the native space of each MPRAGE, as in the previous section, and used to calculate regional [ 18 F]AV-1451 uptake and FDG-PET metabolism in both the gray and white matter, as well as gray matter volumes. For this study, regional values were calculated for the following nine regions-of-interest (ROIs), calculated as voxel weighted medians: temporal pole (merged temporal pole mid and temporal pole sup); lateral temporal cortex (merged inferior temporal, mid temporal and superior temporal cortices); entorhinal cortex, fusiform cortex; orbitofrontal cortex (merged inferior frontal orbital, mid frontal orbital, superior frontal orbital, and medial frontal orbital); medial frontal cortex (merged superior motor area, anterior cingulum, and superior medial frontal); lateral prefrontal cortex (merged middle and superior frontal); Broca's area (merged inferior frontal operculum and inferior frontal triangularis); and inferior parietal cortex (merged inferior parietal, supramarginal, and angular). We selected these ROIs because they are typically involved in the different variants of PPA. 34 in cerebellar crus ([ 18 F]AV-1451) or pons (FDG-PET) to create SUVRs. We measured signal only in voxels segmented as tissue in order to compensate for differing amounts of atrophy across subjects, without the noise-boosting and atrophy/tau signal mixing effects commonly associated with partial volume correction. Total intracranial volume (TIV) was also calculated by summing SPM12 gray, white, and cerebrospinal fluid segmentations. Log transformed gray matter volumes from each region were then regressed by TIV in 80 healthy age-and sex-matched controls, and standardized residuals were calculated from the model using the log-transformed gray matter volumes for each case. The regional [
18 F]AV-1451 SUVRs, FDG-PET SUVRs, and standardized gray matter volumes were then each entered into separate principal component analyses as described below.
Principal Component Analyses
To understand and summarize the underlying structure of the ROI-level data, we ran three principal component analyses (PCAs) based on log-transformed [
18 F]AV-1451 data, logtransformed FDG-PET data, and standardized magnetic resonance imaging (MRI) gray matter volumes from the 40 PPA patients across nine ROIs listed above in each hemisphere. PCA is an "unsupervised" method in that it is blinded to diagnosis and re-expresses the underlying structure of a data set as a series of distinct, uncorrelated dimensions. The first principal component (PC-1) is a weighted sum of regional data where the weights are chosen so that PC-1 has maximum variation across subjects. PC-1 can be thought of as the "best" single-number summary of the regional data in a given modality. The second principal component (PC-2) is a weighted sum of regional data with weight chosen so that (1) PC-2 is completely uncorrelated with PC-1 and (2) PC-2 has maximum variation after accounting for PC-1. A data set with k variables can be described in terms of k principal components, each accounting for progressively less variation in the data. PCA is a tenable tool in regional analyses because of potential drastic reduction the dimensionality of the data without omitting regions while accounting for collinearity of proximally or functionally related regions. All analyses were done using R 37 (version 3.4.1;
R Foundation for Statistical Computing, Vienna, Austria).
Voxel-Level Analysis of [ 18 F]AV-1451 Principal Components
In order to provide spatial maps describing the loadings of the principal components in the [ 
Diagnostic Utility of [ 18 F]AV-1451
Penalized multinomial logistic regression was used within each modality to classify cases based on their regional data into the three diagnoses based on their principal component values. Multinomial regression is an extension of binomial logistic regression that allows for more than two outcomes. An optimal ridge penalty determined by leave-one-out cross-validation for each model was used to limit overfitting while retaining all possible predictors (Principal Components) in the model. 38 Models were fit within each modality of scan ([ 18 F]AV-1451 PET, FDG-PET, and MRI) with varying numbers of principal components. Cross-modality comparisons were made using the proportion of cases reclassified correctly in models using the same number of principal components. All analyses were done using R 37 (version 3.4.1; R Foundation for Statistical Computing).
Results
Of the 40 PPA patients in this study, 14 met international criteria for lvPPA, 13 for svPPA, and 13 for agPPA. Demographic features were similar across variants, although the majority of the lvPPA patients were female (86%), and svPPA patients' median disease duration was 3 years longer than the other two variants at the time of scan. Each PPA variant showed the expected pattern of impairment on the battery of administered clinical tests. All lvPPA patients showed beta-amyloid deposition on PiB-PET, and this variant had a higher median PiB SUVR compared to the svPPA and agPPA variants ( Table 1) . Figure 1 . The lvPPA group showed significantly higher uptake throughout much of the cortex compared to controls, and compared to svPPA and agPPA (Fig 2) . Elevated uptake was particularly observed in the left temporoparietal cortex in lvPPA, with additional involvement of the right temporoparietal cortex and frontal lobes. The svPPA and agPPA groups showed much milder patterns of [ 18 F]AV-1451 uptake compared to controls. The svPPA group showed elevated [ 18 F]AV-1451 uptake bilaterally in the temporal lobes, involving the temporal pole, inferior and middle temporal gyri, fusiform gyrus, amygdala, parahippocampal gyrus, and entorhinal cortex, with greater uptake observed in the left hemisphere than the right hemisphere, compared to controls. The svPPA group also showed a region of mild elevated uptake that predominantly included bilateral rectus gyrus, orbitofrontal cortex, nucleus accumbens, anterior striatum, and anterior insula compared to controls. The svPPA group showed greater uptake in the temporal pole, amygdala, inferior and middle temporal gyri, fusiform gyrus, parahippocampal gyrus, entorhinal cortex, nucleus accumbens, and anterior insula compared to agPPA (Fig 2) . No regions showed greater uptake in svPPA compared to lvPPA.
The agPPA group showed moderately elevated [ 18 F]AV-1451 uptake throughout the white matter of the prefrontal lobe, including orbitofrontal, inferior, middle and superior regions, and temporal lobe, with greater uptake in the left hemisphere, compared to controls. Elevated uptake was also observed in subcortical gray matter structures, including bilateral thalamus, putamen, and globus pallidus, with greater uptake observed in the left hemisphere compared to the right hemisphere. The agPPA group showed greater uptake in the left prefrontal white matter, superior putamen, and thalamus compared to svPPA (Fig 2) . No regions showed greater uptake in agPPA compared to lvPPA.
Representative Table 2 shows the loadings of these two principal components for the ROIs, and Figure 5 shows voxel-level correlations between [ 18 F]AV-1451 uptake and the loadings of the two principal components. We interpret the first principal component (PC-1) as an overall tau severity measure given that the ROI loadings are all of the same sign and essentially the same magnitude. The voxel-level maps similarly illustrate a negative correlation between the loading on PC-1 and [
18 F]AV-1451 in much of the cortex, particularly in temporoparietal and frontal regions (Fig 5) , implying that a greater negative loading is associated with greater [ 18 F]AV-1451 binding in these areas. We interpret the second principal component (PC-2) as a dimension representing a contrast between frontal and temporal regions. That is, after accounting for severity summarized in PC-1, PC-2 locates individuals on a spectrum ranging from relatively high temporal uptake and relatively low frontal uptake to relatively low temporal uptake and relatively high frontal uptake. This is illustrated in Figure 5 where a negative correlation is observed between PC-2 loading and medial and lateral temporal lobe [ The plot in Figure 6 shows the separation of the three PPA variants according to PC-1 and PC-2 that were calculated from the PCA using the ROI data from each of the three modalities. For [ 18 F]AV-1451, all lvPPA patients were more severe than average (ie, to the left of the mean on the PC-1 axis in Fig 6) with this dimension discriminating perfectly between lvPPA and the other two variants (area under the receiver operator curve 5 1; p < 0.001). After accounting for severity, if we look at the PC-2 axis, we see perfect separation of the agPPA and svPPA patients (area under the receiver operator curve 5 1; p < 0.001). In other words, a combination of higher uptake in frontal regions and relatively reduced uptake in temporal regions effectively distinguish agPPA and svPPA.
The penalized multinomial logistic regression models show that [
18 F]AV-1451 outperformed both FDG-PET and MRI when using two principal components (Fig 6) . When considering from three to seven principal components, [
18 F]AV-1451 and FDG-PET were comparable while both consistently outperformed MRI (Fig 6) . These penalized models provide a fair estimate of the ability of these different scan modalities to discriminate between these three diagnoses, showing stronger signals in [ 18 F]AV-1451 and FDG-PET than MRI. regions of increased uptake identified in our lvPPA patients were similar to the regions reported in the three other [
Discussion
18 F]AV-1451 studies and are the same regions that are structurally and functionally most involved in lvPPA. [39] [40] [41] ]AV-1451 is the best of the three imaging modalities, given that with just two principal components it had the best discriminatory value, and the fact that the loadings showed that a simple diagnostic algorithm first accounting for uptake severity followed by frontal versus temporal uptake was all that was needed for almost perfect prediction; similar predictive power with FDG-PET required at least three principal components. Regardless, these findings further support the notion that [ The strengths of this study are that all patients were well characterized clinically and that all 120 patients and healthy controls underwent identical imaging protocols. Holding acquisition and analysis parameters constant allows for a more confident comparison of results. In addition, our PCA was unsupervised, allowing us to assess variability in uptake, metabolism, and volumes unbiased by clinical diagnosis. The lack of autopsy confirmation is a limitation and it is possible that some of our agPPA and svPPA patients may share the same underlying pathology, such as Pick's disease, in which [ 18 F]AV-1451 binding characteristics are unknown and autoradiographic findings are unclear. 12 Other limitations of this study include the relatively small sample size and the possibility of participation or other selection biases. The findings from this study reveal that [
18 F]AV-1451 has potential to differentiate the PPA variants and to be utilized as a diagnostic tool. However, the lack of a credible biological explanation for the elevated uptake in svPPA and agPPA make it less appealing as a biomarker, at present. What is critically needed is to understand what the ligand is binding to in cases that lack pathological evidence for the presence of 3R14R tau.
